Sectors
FULC
Fulcrum Therapeutics, Inc.
3.75
9 x 3.72
36 x 3.75
bid
ask
-
0.00
0.11%
09:39 AM
timesize
| Ytd | -66.88% | |
| 1y | -40.91% |
3.75
day range
3.77
2.83
52 week range
15.74
| Open | 3.77 | Prev Close | 3.75 | Low | 3.75 | High | 3.77 | Mkt Cap | 202.92M |
| Vol | 69.88K | Avg Vol | 2.61M | EPS | -1.15 | P/E | -3.26 | Forward P/E | -3.84 |
| Beta | 3.05 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-27 | 50-d Avg | 3.75 | 200-d Avg | 7.79 | 1yr Est | 5.29 |
| Income Statement | |||
| Operating Expenses | 29.31M | ||
| Research and Development Expense | 12.44M | ||
| Selling, General and Administrative Expense | 7.46M | ||
| Operating Income | -29.31M | ||
| Net Income | -26.18M | ||
| Net Income Common Stock | -26.18M | ||
| Net Income Common Stock (USD) | -26.18M | ||
| Consolidated Income | -26.18M | ||
| Earnings per Basic Share | -0.34 | ||
| Earnings per Basic Share (USD) | -0.34 | ||
| Earnings per Diluted Share | -0.34 | ||
| Earning Before Interest & Taxes (EBIT) | -26.18M | ||
| Earning Before Interest & Taxes (USD) | -26.18M | ||
| Weighted Average Shares | 76.26M | ||
| Weighted Average Shares Diluted | 76.26M | ||
| Balance Sheet | |||
| Cash and Equivalents | 49.56M | ||
| Cash and Equivalents (USD) | 49.56M | ||
| Investments | 270.37M | ||
| Investments Current | 270.37M | ||
| Current Assets | 322.85M | ||
| Total Assets | 323.95M | ||
| Debt Current | 2.52M | ||
| Total Debt | 5.28M | ||
| Current Liabilities | 10.30M | ||
| Debt Non-Current | 2.76M | ||
| Total Liabilities | 13.26M | ||
| Accumulated Retained Earnings (Deficit) | -639.35M | ||
| Accumulated Other Comprehensive Income | -567.00K | ||
| Shareholders Equity | 310.70M | ||
| Shareholders Equity (USD) | 310.70M | ||
| Assets Non-Current | 1.10M | ||
| Total Debt (USD) | 5.28M | ||
| Liabilities Non-Current | 2.96M | ||
| Trade and Non-Trade Payables | 3.43M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 216.00K | ||
| Net Cash Flow from Financing | 356.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -1.90M | ||
| Capital Expenditure | 342.00K | ||
| Issuance (Purchase) of Equity Shares | 356.00K | ||
| Net Cash Flow from Investing | 13.78M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 13.44M | ||
| Net Cash Flow from Operations | -16.04M | ||
| Share Based Compensation | 3.27M | ||